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Introduction 
Atopic dermatitis  (AD) is a chronic and recurrent inflammatory skin disease with a typical 
characteristic of eczematous lesions (1, 2). This condition is usually found in patients during 
infancy and early childhood, but the symptoms sometimes persist until adulthood (2). Although 
skin lesions with age-specific patterns are sufficient clues for the diagnosis of AD, the 1980 
Hanafin and Rajka criteria are useful for making a diagnosis in general practice (3).  
 A pruritic rash is a common clinical presentation that is sometimes accompanied by 
skin infections in patients with AD (2), particularly Staphylococcus. aureus and herpes simplex 
virus (HSV) (4-10). However, fungi (e.g. Malassezia or Candida species) usually colonize on 
the skin of AD patients but the role of these fungi in the pathogenesis of AD remains unclear. 
For example, Malassezia species are part of the normal flora residing on the skin, and while 
these are not normally associated with dermatological conditions, these organisms can 
sometimes cause skin diseases in AD patients (11, 12). In contrast, Candida species, which are 
also present as normal flora on the skin and mucous membranes, are the most common 
pathogenic yeasts causing mucocutaneous candidiasis (13-15). Other fungi (e.g. dermatophytes) 
can also cause fungal infections of skin, hair, and nails in AD patients (16). In this review, the 
epidemiology, pathogenesis, clinical manifestations, diagnosis, and management of 
Malassezia, Candida, and dermatophyte infections in AD patients are discussed (Table 1).  
 
Epidemiology of fungi and atopic dermatitis 
There are a number of fungi associated with AD. Malassezia yeasts are one of the most 
common fungi associated with AD especially in the head-neck lesion of adult patients (11, 12, 17, 
18). In healthy individuals, Malassezia globosa and Malassezia restricta are the most common 
species (19, 20), but a number of studies have revealed no difference in the number of Malassezia 
species isolated from the skin of both healthy and AD patients (11, 21-23), suggesting that these 
fungi are opportunistic organisms in AD. Nonetheless, the level of Malassezia colonization 
was different depending on the severity of AD, i.e. increased up to 2-5 fold in severe AD 
compared to mild or moderate cases (23). Moreover, the Malassezia species that are detected on 
the lesions of AD patients are different depending on the geographical area (19, 20, 24, 25). Sugita, 
et al. proposed that pathogenic strains of M. restricta may be associated with the exacerbation 
of AD (23, 26). Interestingly, serum Malassezia-specific IgE is found in 30% of children with 
AD, and 70% of adult patients (27-30), particularly in patients with head and neck lesions (31). It 
is believed that Malassezia sensitization is correlated with adults more than children with AD 
(30, 32), partly because of less sebum production in children.  
 The association between Candida species colonization or infections and the severity of 
AD is unknown (13, 33). Candida cultures from the gastrointestinal tract and nasopharynx are 
found more in patients with AD than healthy controls (15, 34). It is hypothesized that the 
inappropriate use of topical and systemic antibiotics and corticosteroids probably affects the 
skin and mucosal microbiota to favor the growth of Candida species (35).  However, some 
previous studies showed that Candida species colonization in the oral cavity of AD patients 
was not significantly different compared to healthy controls (36, 37). Therefore, the epidemiology 
of Candida species and AD still needs further investigation. 
 The epidemiology of Trichophyton, Epidermophyton, and Microsporum species and 
their role in the pathology of AD patients are still largely unknown. It has been reported that 
79% of AD patients with dermatophyte infections show an immediate-type hypersensitivity 
reaction against Trichophyton antigen  (a purified trichophytin) in the skin prick test (38). The 
association between atopic diseases and dermatophyte infections with increased total IgE and 
Trichophyton-specific IgE levels is known as the atopic-chronic dermatophytosis syndrome 
(39). These reports suggest that AD patients are more sensitive to these fungi than healthy 
individuals. 
 Recent microbiome studies in AD patients showed that Malassezia species accounted 
for 63-86% of all fungi, followed by non-Malassezia yeasts, such as Candida albicans, 
Cryptococcus species, and other filamentous fungi (40, 41). However, the species of non-
Malassezia yeasts and other filamentous fungi detected are highly variable in individual AD 
patients compared to healthy individuals while Malassezia species are consistently detected (40, 
41). Furthermore, the species of Malassezia detected and the ratio between M. restricta and M. 
globosa, are different depending on the AD severity (41, 42). It has been reported that the ratio 
of M. restricta and M. globosa is > 1:1 in mild to moderate AD patients, while this ratio is 
close to 1 in severe cases (41, 42), suggesting that this ratio could probably be used to predict 
disease severity in AD patients. 
 
Pathogenesis of fungi in AD 
As the pathogenesis of AD can be associated with genetic predisposition, dysregulation of the 
immune system and environmental exposure (43, 44), patients with AD usually have skin barrier 
defects and decreased production of antimicrobial peptides leading to skin infections (45). The 
common pathogens found in AD patients are S. aureus, herpes simplex virus, molluscum 
contagiosum virus, and the fungi described above (46-50).  
Malassezia species easily invade through the skin barrier of AD patients causing skin 
infections. These species contact directly or indirectly with human keratinocytes and other 
immune cells leading to immune activation (12, 51). It has been reported that Toll-like receptors 
type 2 and 4 of human keratinocytes and dendritic cells are stimulated by Malassezia species 
causing secretion of antimicrobial peptides and cytokines (e.g. human b-defensin 2 and 
CXCL8) (52, 53). Malassezia species also activate human dendritic cells via NLRP3 
inflammasome leading to the production of IL-1b, IL-4, IL-5, and IL-13 (54). Moreover, it has 
been demonstrated that nanovesicles secreted by M. sympodialis activate skin dendritic cells 
and dermal mast cells to release TNF-a, IL-6, IL-8, IL-10, and IL-12p70 leading to disease 
exacerbation (55). Taken together, skin barrier defects and immune activation by Malassezia 
species in AD patients are very likely to contribute to Malassezia infections and skin 
inflammation. 
              It has been demonstrated that patients with AD usually develop skin sensitization by 
Candida species as a positive reaction to C. albicans in the skin prick test is found in 27-94% 
of these patients (56, 57). Moreover, total serum IgE levels are elevated in AD patients and 
include an increase in specific C. albicans IgE levels, which is higher than in other allergic 
diseases and healthy controls (13, 15, 58). It has been reported that specific C. albicans IgE levels 
are associated with disease severity in adult patients but not in children (13, 27). However, 
previous studies demonstrated that C. albicans-specific IgE could cross-react between 
Malassezia species, S. cerevisiae polysaccharides and other Candida species leading to a high 
incidence of specific IgE levels in AD patients (13, 59). This cross-reaction could over-estimate 
the incidence of C. albicans and the association with AD. 
 Similarly, immune activation by dermatophytes has been reported in AD patients as an 
immediate-type hypersensitivity reaction to Trichophyton antigen is observed (60, 61) 
particularly in patients with chronic noninflammatory dermatophytosis (16, 60). The immediate 
hypersensitivity type 1 and atopic diseases may be related because they both activate the Th2 
signaling pathway (16, 62). However, other factors (e.g. human leukocyte antigens or HLAs) may 
play a role in this immune activation, which needs to be further investigated (63). Immediate 
hypersensitivity to other molds such as Penicillium, Cladosporium species has also been 
reported (64). Nevertheless, no reports have demonstrated an actual relationship between 
dermatophytes (including Epidermophyton and Microsporum) and AD pathogenesis (65, 66).  
 
Clinical manifestations of fungi and atopic dermatitis  
As mentioned earlier, AD causes skin barrier defects and decreased antimicrobial peptide 
production (45). Fungi that are usually normal flora are able to colonize and sometimes cause 
an infection on AD skin. 
1. Malassezia species 
Malassezia infection manifests as different skin diseases in AD, e.g. pityriasis versicolor of the 
skin, Malassezia folliculitis of the hair follicle. The clinical manifestations of pityriasis 
versicolor usually are multiple hyper or hypo-pigmented macules with fine white scales on the 
seborrheic area such as eyebrows, nasolabial folds, cheek, chin and upper chest (19). However, 
some lesions at the upper back and shoulders could be overlooked and left untreated in AD 
(Fig. 1A). Moreover, pityriasis versicolor found in adolescents and young adults with high 
sebaceous activity commonly has no symptoms, which could be neglected by the patient 
themselves. Tropical climates, hyperhidrosis, and corticosteroid use are believed as other 
predisposing factors of pityriasis versicolor in AD patients (25). 
 Malassezia (Pityrosporum) folliculitis usually presents as mild pruritic monomorphous 
papules and/or pustules without comedones at the neck, upper chest and back, and upper arms 
(Fig. 1B) (25). Malassezia folliculitis is often under-diagnosed or misdiagnosed as acne vulgaris 
(67). It is now recognised that predisposing factors for Malassezia folliculitis in AD patients are 
hot and humid tropical climates, oral corticosteroid (over-)use, topical or oral antibiotic use 
and immunosuppression (67).  
2. Candida species 
Cutaneous candidiasis shows erythematous patches or plaques with satellite papules or pustules 
at the intertriginous area such as the neck, axillae, buttocks including genitalia (14, 15, 36). As the 
clinical manifestations of cutaneous candidiasis at diaper areas (Fig. 1C) sometimes show 
eczematous lesions, the patients are often misdiagnosed with irritant contact dermatitis (diaper 
rash) rather than AD and treated with topical corticosteroids that could favor further Candida 
infection upon the lesions.  
 The association between oral candidiasis and AD is still unknown. However, Candida 
was more frequently isolated from the oral cavity of AD patients compared to healthy controls 
(23% VS 6%) (36). This suggests that AD patients may be prone to Candida colonization in 
both the skin and oral cavity. Moreover, dental caries associated Candida colonization was 
found to be more prevalent in children with AD compared to healthy controls (68). 
3. Dermatophytes  
Dermatophyte infections are found as classic annular or ringworm-like lesions with 
inflammation and a scaly active border  (2). As the clinical manifestations of dermatophytosis 
are scaly pruritic erythematous rashes, it is sometimes difficult to differentiate this infection 
from eczematous lesions in AD patients (Fig. 2). Moreover, dermatophytosis should be more 
suspected particularly in AD patients who have been treated with standard treatments without 
improvement (e.g. tinea incognita) (Fig. 1D). Tinea incognita occurs when corticosteroid 
therapy is used to treat dermatophyte infections, which can mask the lesion. Therefore, it is 
very important to emphasize to general practitioners and dermatologists that a simple direct 
examination (e.g. KOH preparation, Gram staining) is a very helpful but simple laboratory 
investigation to identify these fungal infections in AD patients.  
 
Diagnosis of fungal infections in AD 
Skin scraping with potassium hydroxide (KOH) preparation or Gram staining is the most 
common and easiest method to distinguish types of fungi under light microscopy. However, 
Periodic Acid Schiff (PAS) staining is sometimes helpful particularly in hair and nail fungal 
infections. 
 Malassezia colonization (normal flora) and Malassezia from the skin of Malassezia 
folliculitis lesions are seen as broad-based budding yeasts in KOH preparation under light 
microscopy from healthy skin whilst both budding yeasts and short hyphae are observed from 
pityriasis versicolor lesions (Fig. 3A) (25). Cutaneous candidiasis shows narrow-based budding 
yeasts, pseudohyphae and septate hyphae using KOH preparation and Gram staining (Fig. 3C, 
3D) (69) but hyaline septate hyphae with arthroconidia are found from the scales of active lesions 
in dermatophytosis (Fig. 3B) (69).  
 Calcofluor white and blankophor (0.1%, w/v) or Chicago sky blue stain, together with 
20% KOH preparation (1:1, v/v) can also be utilized to assist detection of fungal elements in 
some reports (70, 71). Calcofluor white and blankophor bind to chitin on the fungal cell wall and 
fungal elements are identified under fluorescent microscopy with 400-440 nm blue filter while 
Chicago sky blue directly binds to the fungal elements, which are easily seen under light 
microscopy (blue fungal elements with a pink background). Sensitivity and specificity of both 
stains are comparable (72-74), but the Chicago sky blue stain is more cost-effective . Therefore, 
the Chicago sky blue stain can be used as a novel rapid technique for diagnosis of fungal skin 
infections (72, 73, 75, 76). 
 Although fungal culture is important to confirm fungal species (2), it is not a routine 
laboratory test for AD patients (13, 77). Malassezia species need long-chain fatty acids to grow 
in culture media while Candida species are cultured in conventional media and identified using 
biochemical tests and molecular identification. Dermatophytes can also be cultured and 
identified using their typical morphologies and molecular identification (69). For Malassezia 
and Candida yeasts, biochemical tests are sugar assimilation assays that can differentiate the 
pattern of carbon utilization among yeasts (13, 77). Molecular identification using PCR-
sequencing with pan-fungal primers (ITS, internal transcribed spacer) is needed if the 
biochemical assays or morphological identifications are inconclusive (77). 
 
Management of atopic dermatitis and fungi 
Management of atopic dermatitis involves patient education, appropriate skin hydration, 
irritant removal, anti-inflammatory therapy, antipruritic medications, and treatment of 
infections (2). The first-line treatment of AD is emollients for hydration and topical 
corticosteroid for anti-inflammation including topical immunomodulators (2, 78-80).  
 Emollients (e.g. fatty acids, cholesterol, squalene) improve skin texture and reduce 
water loss (81-83). However, emollients with fragrances are not recommended because of skin 
irritation and contact dermatitis (83, 84). Furthermore, certain types of emollients containing olive 
oil should be avoided as they may affect stratum corneum homeostasis and support Malassezia 
growth leading to further fungal infections (83, 85). Humectants (e.g. urea, glycerol, panthenol) 
and occlusive agents (e.g. mineral oil, beeswax, petroleum jelly, silicones, zinc oxide) are 
beneficial and sometimes added for further skin hydration in AD patients (83, 84). Regarding 
treatment with topical corticosteroids, long term use should be carefully considered as it 
suppresses the immune responses on the skin of patients and could lead to prolonged infections 
and complications (86).   
AD patients with Malassezia infections, e.g. pityriasis versicolor, Malassezia 
folliculitis, can be treated with topical and/or systemic antifungal therapy but patients with 
Malassezia-exacerbated AD are usually refractory to the standard treatments (e.g. emollients 
and topical corticosteroids), especially with head and neck lesions (50, 87, 88). The symptoms of 
these AD patients can be ameliorated by systemic therapy (e.g. azoles) (89, 90). There are several 
types of antifungal agents used but azoles are usually the treatment of choice (13). Furthermore, 
azoles also show an anti-inflammatory effect on the skin of AD patients as they inhibit IL-4 
and IL-5 production by T cells (91). Interestingly, topical calcineurin inhibitors (e.g. tacrolimus) 
inhibit skin inflammation in AD patients and have an antifungal effect on Malassezia species 
together with a synergistic effect with azoles (i.e. ketoconazole and itraconazole) (92).  
Treatment of Candida infections in AD patients is similar to Malassezia-associated AD 
treatment (93, 94). Previous reports showed that antifungal treatment (e.g. ketoconazole and 
fluconazole) can decrease symptoms and serum IgE levels especially in refractory AD patients 
(90, 93, 95-97). Importantly, when these Malassezia and Candida infections are found in AD 
patients, antifungal therapy should be used (86). Anti-inflammatory therapy, such as tacrolimus, 
and emollients with antifungal therapy are preferred over topical corticosteroid therapy for 
Malassezia and Candida infections (13, 25). However, clinical judgment and close follow-up are 
essential to effectively treat AD patients with Malassezia or Candida infections. 
 The effectiveness of antifungal treatment in AD patients with dermatophytosis has 
been demonstrated in many studies (13, 16). Topical and systemic azoles, including topical 
allylamines, e.g. terbinafine, are still the first-line treatment of these skin infections but 
systemic therapy is selected once a large area of the skin or hair and nail are infected (2, 98, 99). 
For example, it has been reported that recalcitrant AD patients with nail infections (tinea 
unguium) and Trichophyton-specific IgE are clinically improved after systemic antifungal 
treatment (100). Furthermore, severe generalized deep dermatophytosis, trichophytic 
granuloma in AD patients were eliminated after 200 mg/day itraconazole treatment for 4 
months (2, 100-102). 
Conclusion 
AD is a chronic skin disease and fungal skin infections, e.g. Candida species, Malassezia 
species, and dermatophytes, can deteriorate and exacerbate this condition in some patients. 
Fungal skin infections are probably not the cause of AD but skin barrier defects and decrease 
in anti-microbial peptide production on the skin in AD patients allow fungi to penetrate easily 
into the epidermal layer and cause fungal allergen hypersensitivity in these patients. It is very 
important to emphasize that fungal infections are one of the differential diagnoses and need to 
be excluded particularly in recalcitrant cases. The standard antifungal treatment along with 
conventional AD therapy can result in clinical improvement in AD patients. However, further 
studies on the effectiveness of the antifungal treatment are required for the selection of the 
specific antifungal agents or the combination of treatment between immunomodulators and 
antifungal agents. This knowledge could improve the prognosis and quality of life of AD 
patients, especially with fungal skin infections. 
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Table 1. Clinical manifestations, diagnosis, and management of fungi associated with 
AD (KOH: potassium hydroxide preparation; AD: atopic dermatitis) 
Fungi associated 
with AD 






molecular tests (optional)  
Topical azole treatment (e.g. 
ketoconazole 2%, econazole 1% , 
miconazole 2%), 50% propylene 
glycol in water twice-daily for 3-4 
weeks (87, 88) 
Systemic azole treatment (200mg 
of itraconazole for 2 weeks) for 
head-and-neck lesions (2, 89, 90) 
Candida species 




molecular tests (optional) 
Topical azole treatment  
(clotrimazole 1% or miconazole 2% 
twice daily for 1-2 weeks) 
(Nystatin cream 100,000 units/g  in 
case of imidazole allergy) (93) 
Systemic azole treatment 
(fluconazole 150 mg  single dose) 
in refractory cases (2, 90, 94-97) 
Dermatophytes 
Annular or ringworm-like lesion 
with scaly active border 
KOH, culture with 
microscopic morphology, 
molecular tests (optional) 
Topical antifungal drugs e.g. 
azoles, allylamines, butenafine, 
ciclopirox, and tolnaftate once or 
twice daily for 1-3 weeks (98, 99) 
Systemic azole treatment 
(200mg/day itraconazole) in 
recalcitrant AD with dermatophyte 















































Figure 3.  
